  In this paper, we propose using mobile nanosensors (MNSs) for early stage
anomaly detection. For concreteness, we focus on the detection of cancer cells
located in a particular region of a blood vessel. These cancer cells produce
and emit special molecules, so-called biomarkers, which are symptomatic for the
presence of anomaly, into the cardiovascular system. Detection of cancer
biomarkers with conventional blood tests is difficult in the early stages of a
cancer due to the very low concentration of the biomarkers in the samples
taken. However, close to the cancer cells, the concentration of the cancer
biomarkers is high. Hence, detection is possible if a sensor with the ability
to detect these biomarkers is placed in the vicinity of the cancer cells.
Therefore, in this paper, we study the use of MNSs that are injected at a
suitable injection site and can move through the blood vessels of the
cardiovascular system, which potentially contain cancer cells. These MNSs can
be activated by the biomarkers close to the cancer cells, where the biomarker
concentration is sufficiently high. Eventually, the MNSs are collected by a
fusion center (FC) where their activation levels are read and exploited to
declare the presence of anomaly. We analytically derive the biomarker
concentration as well as the probability mass function of the MNSs' activation
levels and validate the obtained results via particle-based simulations. Then,
we derive the optimal decision rule for the FC regarding the presence of
anomaly assuming that the entire network is known at the FC. Finally, for the
FC, we propose a simple sum detector that does not require knowledge of the
network topology. Our simulations reveal that while the optimal detector
achieves a higher performance than the sum detector, both proposed detectors
significantly outperform a benchmark scheme that used fixed nanosensors at the
FC.
